Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3817

Sort by

Sort Order Select

Journal Articles

Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism

Bethany Verkamp, Sonata Jodele, Anthony Sabulski, Rebecca Marsh, Pearce Kieser, Michael B. Jordan

Blood (2024) 144 (25): 2625–2636.

https://doi.org/10.1182/blood.2024025977

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Holly Lee, Michael Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, David Jung, Noémie Leblay, Bachisio Ziccheddu, Benjamin Diamond, Marios Papadimitriou, Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis

Blood (2024) 144 (25): 2637–2651.

https://doi.org/10.1182/blood.2024026212

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T-cells in autoimmunity: game changer or stepping stone?

Dimitrios Mougiakakos, Everett Meyer, Georg Schett

Blood blood.2024025413.

https://doi.org/10.1182/blood.2024025413

Published: 2024

Includes: Supplemental data

Journal Articles

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma

Blood (2024) 144 (24): 2490–2502.

https://doi.org/10.1182/blood.2024024381

Published: 2024

Includes: Supplemental data

Journal Articles

Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy

Michael A. Cole, Nikhil Ranjan, Gloria F. Gerber, Xiang-Zuo Pan, Daniel Flores-Guerrero, George McNamara, Shruti Chaturvedi, C. John Sperati, Keith R. McCrae, Robert A. Brodsky

Blood (2024) 144 (24): 2528–2545.

https://doi.org/10.1182/blood.2024025850

Published: 2024

Includes: Supplemental data

Journal Articles

T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities

Jingqiong Hu, Cynthia E. Dunbar

Blood (2024) 144 (24): 2473–2481.

https://doi.org/10.1182/blood.2024025828

Published: 2024

Journal Articles

Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes

Blood blood.2024024965.

https://doi.org/10.1182/blood.2024024965

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Blood (2024) 144 (23): 2375–2388.

https://doi.org/10.1182/blood.2023023616

Published: 2024

Includes: Supplemental data

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Honing CAR T cells to tackle acute myeloid leukemia

Sascha Haubner, Marion Subklewe, Michel Sadelain

Blood blood.2024024063.

https://doi.org/10.1182/blood.2024024063

Published: 2024

Journal Articles

Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited

Jan-Inge Henter, Elena Sieni, Julia Eriksson, Elisabet Bergsten, Ida Hed Myrberg, Scott W. Canna, Maria Luisa Coniglio, Randy Q. Cron, Kate F. Kernan, Ashish R. Kumar, Kai Lehmberg, Francesca Minoia, Ahmed Naqvi, Angelo Ravelli, Yong-Min Tang, Matteo Bottai, Yenan T. Bryceson, AnnaCarin Horne, Michael B. Jordan

Blood (2024) 144 (22): 2308–2318.

https://doi.org/10.1182/blood.2024025077

Published: 2024

Includes: Supplemental data

Journal Articles

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML

Harrison Silva, Grace Martin, Filippo Birocchi, Marc Wehrli, Michael C Kann, Valentina M Supper, Aiyana Parker, Charlotte E Graham, Alexandra Grace Bratt, Amanda A Bouffard, Hannah Donner, Giulia Escobar, Hana N Takei, Alexander Armstrong, Sadie Goncalves, Trisha R Berger, Bryan D. Choi, Marcela V Maus, Mark B Leick

Blood blood.2023023210.

https://doi.org/10.1182/blood.2023023210

Published: 2024

Includes: Supplemental data

Journal Articles

Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia

Jihong Ma, Zhaohui Wang, Danielle Mintzlaff, Huiping Zhang, Rashmi Ramakrishna, Eduardo Davila, Matthew T. Witkowski, M Scott Lucia, Marc S. Schwartz, Elizabeth A. Pomfret, David W. Mathes, Zhirui Wang

Blood blood.2024025277.

https://doi.org/10.1182/blood.2024025277

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy

Xavier Deschênes-Simard, Bianca D. Santomasso, Parastoo B. Dahi

Blood (2024) 144 (20): 2083–2094.

https://doi.org/10.1182/blood.2024025679

Published: 2024

Journal Articles

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood (2024) 144 (20): 2121–2135.

https://doi.org/10.1182/blood.2024024590

Published: 2024

Includes: Supplemental data

Journal Articles

New insights into the biology of T-cell lymphomas

Javeed Iqbal, Giorgio Inghirami, Wing C. Chan

Blood (2024) 144 (18): 1873–1886.

https://doi.org/10.1182/blood.2023021787

Published: 2024

Includes: Supplemental data

Journal Articles

Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma

Jing Nie, Chunmeng Wang, Liangtao Zheng, Yang Liu, Chengcheng Wang, Yixin Chang, Yudi Hu, Bing Guo, Yuting Pan, Qingming Yang, Xueda Hu, Weidong Han

Blood (2024) 144 (18): 1936–1950.

https://doi.org/10.1182/blood.2024024487

Published: 2024

Includes: Supplemental data

Journal Articles

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Blood blood.2024025987.

https://doi.org/10.1182/blood.2024025987

Published: 2024

Includes: Supplemental data

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood blood.2024025366.

https://doi.org/10.1182/blood.2024025366

Published: 2024

Includes: Supplemental data

Journal Articles

Conserved helical motifs in the IKZF1 disordered region mediate NuRD interaction and transcriptional repression

Tianyi Zhang, Yi-Fang Wang, Alex Montoya, Ilinca Patrascan, Nehir Nebioglu, Husayn A Pallikonda, Radina Georgieva, James WD King, Holger B Kramer, Pavel V Shliaha, David S. Rueda, Matthias Merkenschlager

Blood blood.2024024787.

https://doi.org/10.1182/blood.2024024787

Published: 2024

Includes: Supplemental data

NARROW

Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

CAR T-cells in autoimmunity: game changer or stepping stone?

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma

Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy

T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities

Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Honing CAR T cells to tackle acute myeloid leukemia

Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML

Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia

Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

New insights into the biology of T-cell lymphomas

Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Conserved helical motifs in the IKZF1 disordered region mediate NuRD interaction and transcriptional repression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only